Haoxi Health Technology (HAO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2026, filed Sep 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HAO SEC filings page.
Haoxi Health Technology Limited (HAO) reported $54.8M in revenue for fiscal year 2026, up 67.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovered in FY2026, but costs outran sales, leaving a financing-supported model with sharply negative operating margins.
FY2026 revenue rose67.1% from FY2025, yet gross profit fell32.2% , showing that added sales came with weaker economics rather than flowing through to earnings. SG&A expansion rose204.9% over the same period, helping push operating margin to-17.6% .
Gross margin fell 4.5 percentage points from FY2024 to FY2026, ending at
FY2026 operating cash flow was
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Haoxi Health Technology Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Haoxi Health Technology Limited has an operating margin of -17.6%, meaning the company loses $18 on every $100 of revenue. This results in a profitability score of 16/100. This is down from -6.1% the prior year.
Haoxi Health Technology Limited's revenue surged 67.1% year-over-year to $54.8M, reflecting rapid business expansion. This strong growth earns a score of 54/100.
With a current ratio of 4.53, Haoxi Health Technology Limited holds $4.53 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.
Haoxi Health Technology Limited posts a -53.4% return on equity (ROE), meaning it loses $53 for every $100 of shareholders' equity. This results in a returns score of 7/100. This is down from 22.3% the prior year.
Haoxi Health Technology Limited scores 1.59, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $9.7M against total assets of $21.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Haoxi Health Technology Limited passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Haoxi Health Technology Limited reported a net loss of $9.5M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Haoxi Health Technology Limited reported an operating loss of $9.7M against $52K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Haoxi Health Technology Limited generated $54.8M in revenue in fiscal year 2026. This represents an increase of 67.1% from the prior year.
Haoxi Health Technology Limited's EBITDA was -$9.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Haoxi Health Technology Limited reported a net loss of $9.5M in fiscal year 2026. This represents a decrease of 346.0% from the prior year.
Haoxi Health Technology Limited earned -$386.40 per diluted share (EPS) in fiscal year 2026.
Cash & Balance Sheet
Haoxi Health Technology Limited held $10.9M in cash as of fiscal year 2026; no long-term debt figure is on record for that period.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
Haoxi Health Technology Limited's gross margin was 1.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 1.7 percentage points from the prior year.
Haoxi Health Technology Limited's operating margin was -17.6% in fiscal year 2026, reflecting core business profitability. This is down 11.5 percentage points from the prior year.
Haoxi Health Technology Limited's net profit margin was -17.4% in fiscal year 2026, showing the share of revenue converted to profit. This is down 29.2 percentage points from the prior year.
Haoxi Health Technology Limited's ROE was -53.4% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 75.7 percentage points from the prior year.
Capital Allocation
Haoxi Health Technology Limited invested $104K in research and development in fiscal year 2026. This represents an increase of 31.2% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
HAO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|---|
| Revenue | $54.8M+67.1% | $32.8M-32.4% | $48.5M+71.9% | $28.2M+74.7% | $16.2M |
| Cost of Revenue | $54.2M+70.0% | $31.9M-30.4% | $45.8M+74.9% | $26.2M+68.7% | $15.5M |
| Gross Profit | $629K-32.2% | $928K-66.3% | $2.8M+33.4% | $2.1M+217.9% | $649K |
| R&D Expenses | $104K+31.2% | $80K-0.6% | $80K+37.5% | $58K-43.3% | $103K |
| SG&A Expenses | $8.7M+204.9% | $2.8M+198.8% | $953K+17.9% | $808K+191.3% | $277K |
| Operating Income | -$9.7Mn/m | -$2.0M-216.5% | $1.7M+43.6% | $1.2M+344.9% | $269K |
| EBITDA | -$9.4Mn/m | -$1.7M-198.7% | $1.7M+43.5% | $1.2M+344.4% | $271K |
| Interest Expense | $52K+14.1% | $46K+11.6% | $41K+108.3% | $20K | N/A |
| Income Tax | $37K-86.5% | $271K-39.0% | $444K+101.0% | $221K+1370.2% | $15K |
| Net Income | -$9.5M-346.0% | $3.9M+200.1% | $1.3M+33.2% | $970K+296.5% | $245K |
| EPS (Basic) | -$386.40 | $4251.81 | $2701.53 | $0.87 | $0.01 |
| EPS (Diluted) | -$386.40 | $3385.53 | $2701.53 | $0.87 | $0.01 |
| Diluted Shares (Avg) | 24,680 | 936 | 478 | 1M | 25M |
HAO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|---|
| Total Assets | $21.6M-0.1% | $21.6M+39.3% | $15.5M+247.4% | $4.5M | N/A |
| Current Assets | $16.8M-14.2% | $19.6M+27.5% | $15.4M+318.6% | $3.7M | N/A |
| Cash & Equivalents | $10.9M+26.9% | $8.6M+29.5% | $6.7M+453.2% | $1.2M+309.9% | $294K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Accounts Receivable | $6K-98.7% | $460K+103.0% | $227K+2826.5% | $8K | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Total Liabilities | $3.7M-12.0% | $4.2M-0.4% | $4.2M+46.1% | $2.9M | N/A |
| Current Liabilities | $3.7M-5.1% | $3.9M+1.2% | $3.9M+50.1% | $2.6M | N/A |
| Non-Current Liabilities | $0-100.0% | $307K-16.5% | $368K+14.6% | $321K | N/A |
| Long-Term Debt | N/A | $307K+1.9% | $302K+21.1% | $249K | N/A |
| Total Equity | $17.9M+2.8% | $17.4M+54.2% | $11.3M+619.6% | $1.6Mn/m | -$1.5M |
| Retained Earnings | -$4.9M-207.5% | $4.6M+536.0% | $723Kn/m | -$568K | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill.
HAO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|---|
| Operating Cash Flow | -$2.6Mn/m | -$3.4Mn/m | -$748Kn/m | -$872Kn/m | -$675K |
| Depreciation & Amortization | $309K+4.8% | $295K+2688.0% | $11K+25.9% | $8K+279.4% | $2K |
| Stock-Based Compensation | N/A | $59K | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | $55K+21.7% | $46K+423.1% | $9K |
| Free Cash Flow | N/A | N/A | -$803Kn/m | -$918Kn/m | -$684K |
| Investing Cash Flow | -$4.5Mn/m | -$3.6Mn/m | -$3.1Mn/m | -$46Kn/m | -$9K |
| Financing Cash Flow | $9.3M+4.8% | $8.9M-4.5% | $9.3M+417.2% | $1.8M+93.2% | $933K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
HAO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|---|
| Gross Margin | 1.1%-1.7pp | 2.8%-2.8pp | 5.7%-1.6pp | 7.3%+3.3pp | 4.0% |
| Operating Margin | -17.6%-11.5pp | -6.1%-9.6pp | 3.5%-0.7pp | 4.2%+2.6pp | 1.7% |
| Net Margin | -17.4%-29.2pp | 11.8%+9.2pp | 2.7%-0.8pp | 3.4%+1.9pp | 1.5% |
| Return on Equity | -53.4%-75.7pp | 22.3%+10.8pp | 11.5%-50.4pp | 61.9% | N/A |
| Return on Assets | -44.2%-62.2pp | 17.9%+9.6pp | 8.3%-13.4pp | 21.7% | N/A |
| Current Ratio | 4.53-0.5x | 5.01+1.0x | 3.98+2.6x | 1.43 | N/A |
| Debt-to-Equity | N/A | 0.020.0x | 0.03-0.1x | 0.16 | N/A |
| Liabilities-to-Equity | 0.210.0x | 0.24-0.1x | 0.38-1.5x | 1.85 | N/A |
| Asset Turnover | 2.54+1.0x | 1.52-1.6x | 3.13-3.2x | 6.32 | N/A |
| FCF Margin | N/A | N/A | -1.7%+1.6pp | -3.3%+1.0pp | -4.2% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Haoxi Health Technology Limited HAO | FY2026 | $54.8M | -$9.5M | -17.4% | $740K | 44/100 |
| ZW Data Action Technologies Inc. CNET | FY2025 | $4.6M | -$1.8M | -38.4% | $3.0M | 33/100 |
| Baosheng Media Group Holdings Limited BAOS | FY2025 | $569K | -$12.0M | N/A | $5.6M | — |
| Star Fashion Culture Holdings Limited STFS | FY2026 | $31.0M | -$4.2M | -13.7% | $70.6M | 52/100 |
| DIRECT DIGITAL HLDGS A DRCT | FY2025 | $34.7M | -$18.9M | -54.6% | $96K | — |
| Cheer Holding, Inc. CHR | FY2025 | $148.8M | $25.6M | 17.2% | $2.9M | 72/100 |
Where Haoxi Health Technology Limited Ranks
Frequently Asked Questions
What is Haoxi Health Technology Limited's annual revenue?
Haoxi Health Technology Limited (HAO) reported $54.8M in total revenue for fiscal year 2026. This represents a 67.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Haoxi Health Technology Limited's revenue growing?
Haoxi Health Technology Limited (HAO) revenue grew by 67.1% year-over-year, from $32.8M to $54.8M in fiscal year 2026.
Is Haoxi Health Technology Limited profitable?
No, Haoxi Health Technology Limited (HAO) reported a net loss of $9.5M in fiscal year 2026, with a net profit margin of -17.4%.
What is Haoxi Health Technology Limited's EBITDA?
Haoxi Health Technology Limited (HAO) had EBITDA of -$9.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Haoxi Health Technology Limited's gross margin?
Haoxi Health Technology Limited (HAO) had a gross margin of 1.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Haoxi Health Technology Limited's operating margin?
Haoxi Health Technology Limited (HAO) had an operating margin of -17.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Haoxi Health Technology Limited's net profit margin?
Haoxi Health Technology Limited (HAO) had a net profit margin of -17.4% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Haoxi Health Technology Limited's return on equity (ROE)?
Haoxi Health Technology Limited (HAO) has a return on equity of -53.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Haoxi Health Technology Limited's operating cash flow?
Haoxi Health Technology Limited (HAO) recorded an outflow of $2.6M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Haoxi Health Technology Limited's total assets?
Haoxi Health Technology Limited (HAO) had $21.6M in total assets as of fiscal year 2026, including both current and long-term assets.
How much does Haoxi Health Technology Limited spend on research and development?
Haoxi Health Technology Limited (HAO) invested $104K in research and development during fiscal year 2026.
What is Haoxi Health Technology Limited's current ratio?
Haoxi Health Technology Limited (HAO) had a current ratio of 4.53 as of fiscal year 2026, which is generally considered healthy.
What is Haoxi Health Technology Limited's liabilities-to-equity ratio?
Haoxi Health Technology Limited (HAO) had a liabilities-to-equity ratio of 0.21 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
What is Haoxi Health Technology Limited's return on assets (ROA)?
Haoxi Health Technology Limited (HAO) had a return on assets of -44.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Haoxi Health Technology Limited's P/E ratio?
Haoxi Health Technology Limited (HAO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $740K as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Haoxi Health Technology Limited's price-to-sales ratio?
Haoxi Health Technology Limited (HAO) trades at 0.0x sales, its market capitalization divided by $54.8M revenue, FY2026. The market capitalization is $740K as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Haoxi Health Technology Limited's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Haoxi Health Technology Limited (HAO) held $10.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.6M over that year. Dividing the one by the other, the reported balance equals about 51 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Haoxi Health Technology Limited's Altman Z-Score?
Haoxi Health Technology Limited (HAO) has an Altman Z-Score of 1.59, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Haoxi Health Technology Limited's Piotroski F-Score?
Haoxi Health Technology Limited (HAO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Haoxi Health Technology Limited's earnings high quality?
Haoxi Health Technology Limited (HAO) reported a net loss of $9.5M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Haoxi Health Technology Limited cover its interest payments?
Haoxi Health Technology Limited (HAO) reported an operating loss of $9.7M against $52K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Haoxi Health Technology Limited?
Haoxi Health Technology Limited (HAO) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.